Resumo
Twenty adult patients presenting dermal cysticercosis without cerebral or ocular involvement were treated with praziquantel. The first eleven cases received 60 mg/kg/day and the last nine cases 30 mg/kg/day. In both groups the daily dose was split into three oral intakes 4 to 6 hours apart and the drug administration lasted for 6 consecutive days. The latter group of patients also got dexamethasone, 3 mg daily, from one day before until four days after the treatment period with praziquantel. The drug proved to be 100% efficacious as demonstrated histopathologically by the death of the cysticerci of Taenia solium (Cysticercus cellulosae) in serial biopsies taken from the 2nd week on after the end of treatment, as well as clinically by the steady disappearence of the dermal nodules during the 6 months following the therapy. Tolerance of praziquantel was good as the incidence and severity of side-effects were not relevant. The drug safety was confirmed through laboratory tests which failed to detect any abnormal findings related to the hematopoietic, liver and kidney functions.
Treatment of dermal cysticercosis with praziquantel (* (* ) CISTICID Merck S.A. Indústrias Químicas ). A new cestocidal agent
Tratamento da cisticercose subcutânea co praziquantel. Um novo agente cestoidicida
Miroslau Constante Baranski
The late Head Professor, Infectious and Parasitic Diseases; Faculdade de Medicina, Universidade Federal do Paraná, Curitiba, Brazil
Correspondence to Correspondence to: Merck S.A. Indústrias Químicas Caixa Postal 55 077 22 700 Rio de Janeiro, RJ, Brasil
SUMMARY
Twenty adult patients presenting dermal cysticercosis without cerebral or ocular involvement were treated with praziquantel. The first eleven cases received 60 mg/kg/day and the last nine cases 30 mg/kg/day. In both groups the daily dose was split into three oral intakes 4 to 6 hours apart and the drug administration lasted for 6 consecutive days. The latter group of patients also got dexamethasone, 3 mg daily, from one day before until four days after the treatment period with praziquantel. The drug proved to be 100% efficacious as demonstrated histopathologically by the death of the cysticerci of Taenia solium (Cysticercus cellulosae) in serial biopsies taken from the 2nd week on after the end of treatment, as well as clinically by the steady disappearence of the dermal nodules during the 6 months following the therapy. Tolerance of praziquantel was good as the incidence and severity of side-effects were not relevant. The drug safety was confirmed through laboratory tests which failed to detect any abnormal findings related to the hematopoietic, liver and kidney functions.
Texto completo disponível apenas em PDF.
Full text available only in PDF format.
ACKNOWLEDGMENTS
To Dr. Ary Fontoura da Silva, Dr. Luiz Maurício Guimarães and Dr. Carlos Alberto Munhoz da Cunha. Hospital de Clinicas da Universidade Federal do Paraná, Curitiba, for their collaboration in the execution of this trial; to Dr. Getúlio Leonel de Rezende. Clinical Research Dpt., Merck S.A.. Rio de Janeiro, for having designed this study.
Recebido para publicação em 3/4/1984.
- 1. BAKANSKI. M. C. GOMES. N. R.; GODO Y, D. F.; SILVA, A. P.; KOTAKA. P. I.; GIOVANNONI, M. de CARNEIRO PILHO, M. Terapêutica da teníase e da Hymenolepíase nana com dose oral única de praziquantel. Estudo de eficácia, tolerância e segurança. Rev. Inst. Med. trop. São Paulo 22: 82-88, 1980.
- 2. CHAVARRIA, M. & GONZÁLEZ, D. D. Praziquantel (Droncit) en el tratamiento de la cisticercosis porcina. Esp. Vet. 1: 159-165, 1978.
- 3. PLISSER, A.; PÈREZ-MONTFORT, R. & LARRALDE, C. The immunology of human cysticercosis: a review. Bull. W.H.O. 57: 839-856, 1979.
- 4. FROHBERG, H. & SCHULZE SCHENCKING, M. Toxicological profile of praziquantel, a new drug against cestode and schistosome infections, as compared to some other schistosomicides. Drug Res. 31: 555-5S5, 1981.
- 5. GALLIE, G. J. & SEWELL, M. M. H. The efficacy of praziquantel against the cysticerci of Taenia saginata in calves. Trop. Anim. HIth. Prod. 10: 36-38, 1978.
- 6. KONOVALONA, L. M. Search for and use of new methods for immunodiagnosis of human cysticercosis. Medskaya Parazit. 42: 536-542, 1973.
- 7. LEOPOLD, G. et al. Clinical pharmacology of praziquantel, a new drug against Schistosomiasis and Ces-todiasis in normal volunteers. Europ. J. Clin. Pharmacol. 14: 69-78, 1978.
- 8. LOUZADA, G. Z. et al. Tratamento da teníase e himenolepíase com dose única, por via oral, de praziquantel. F. méd. (BR) 79: 99-102, 1979.
- 9. MARQUEZ-MONTER, H. Cysticercosis. In MARCIAL-ROJAS, R. A. Pathology of protozoal and helminthic diseases. Baltimore, Williams & Wilkins, 1971.
- 10. RIM, H. J. & WON, G. R. Studies on the human cysticercosis and its therapeutic trial with praziquantel. Korea Univ. Med. J. 17: 459-472, 1980.
- 11. SPINA-FRANÇA, A. & NÓBREGA, J. P. S. Neuro-cisticercose e praziquantel. II Avaliação dos resultados em 20 pacientes. Arq. Neuro-Psiquiat. (São Paulo) 39: 279-281, 1981.
- 12. THOMAS, H. .& GÜNNERT, R. The efficacy of praziquantel against cestode in animals. Z. Parasitenk. 52: 117-127, 1977.
- 13. THOMAS, H. Resultados experimentales con praziquantel en cestodiasis y cisticercosis. Bol. Chile. Parasit. 32: 2-6, 1977.
- 14. THOMAS, H. & GÜNNERT, R. The efficacy of praziquantel against experimental cysticercosis and hy-datidosis. Z. Parasitenk. 55: 165-169, 1978.
- 15. WALTHER, J. & ROSKE, J. K. The efficacy of praziquantel against Taenia saginata cysticercosis in naturally infected calves. Tropenmed. Parasitol. 30: 401-403, 1979.
Datas de Publicação
-
Publicação nesta coleção
08 Abr 2013 -
Data do Fascículo
Out 1984
Histórico
-
Recebido
03 Abr 1984
